Abstract Number: PB1482
Meeting: ISTH 2020 Congress
Theme: Platelet Disorders and von Willebrand Disease » Platelet Function Disorders, Acquired
Background: Rivaroxaban, apixaban and edoxaban are direct oral anticoagulants (DOACs), whose target specificity is to activate factor X (FXa), which is why they are referred to as Xabans. In contemporary cardiology, we see an effort to combine DOACs with antiplatelet therapy. Therefore, it is relevant whether Xabans have additional effects on platelet function. If so, it could affect the bleeding risk and influence the choice of treatment based on the patient risk profile.
Aims: The aim of the present study was to assess the effects of selected Xabans on in vitro platelet aggregation in patients with non-valvular atrial fibrillation (NVAF).
Methods: We assessed light transmittance platelet aggregation (LTA) with 100 nmol/L γ-thrombin. The LTA was performed at two time-points.
Results: Fifty four patients with NVAF were enrolled. All patients began treatment with rivaroxaban, apixaban or edoxaban as an initial anticoagulant treatment. Apixaban doses were 2.5 mg (n=13, 70%) or 5 mg (n=7, 30%) twice a day. Rivaroxaban doses were 15 mg (n=6, 43%) or 20 mg (n=8, 57%) once a day. Edoxaban doses were 30 mg (4, 20%) or 60 mg (16, 80%) once daily. The thrombin-induced platelet aggregation was significantly lower two hours after selected xaban was taken compared to baseline measurement. In addition, we have done 16 subgroup analyses in order to determine the impact on aggregometer measurement. We did not find any significant difference between the groups.
Conclusions: The thrombin-induced platelet aggregation is reduced in NVAF patients receiving Xabans. This should be taken into account in future studies of the combination of DOACs and antiplatelet therapy. The study was supported by grants VEGA 1/0187/17 and APVV-17-0054.
To cite this abstract in AMA style:
Sokol J, Nehaj F, Mokan M, Ivankova J, Lisa L, Zolkova J, Vadelova L, Stasko J. First Evidence: Rivaroxaban, Apixaban and Edoxaban Reduce Thrombin-Dependent Platelet Aggregation [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/first-evidence-rivaroxaban-apixaban-and-edoxaban-reduce-thrombin-dependent-platelet-aggregation/. Accessed March 21, 2024.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/first-evidence-rivaroxaban-apixaban-and-edoxaban-reduce-thrombin-dependent-platelet-aggregation/